MLV-based retroviral vectors were used in both SCID-X1 and ADA-SCID trials, yet in contrast to the SCID-X1 trials no recipients in the ADA-SCID trials developed clonal dominance or leukaemia [84,89,90]. Here, ADA is linked to leukemia.